Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.66 |
| ▸ | HTR2B | P41595 | 13/20 | 0.66 |
| ▸ | KDM1A | O60341 | 5/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.52 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 9/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2826042 | 1.00 | HTR2C (0.66) | HTR2CHTR2BKDM1AMAOBKCNH2 | |
| SCHEMBL4893904 | 1.00 | HTR2C (0.66) | HTR2CHTR2BKDM1AMAOBKCNH2 | |
| SCHEMBL2830644 | 0.84 | HTR2C (0.61) | HTR2CHTR2BKDM1AMAOBKCNH2 | |
| SCHEMBL2829240 | 0.84 | HTR2C (0.61) | HTR2CHTR2BKDM1AMAOBKCNH2 | |
| SCHEMBL16585035 | 0.79 | HTR2C (0.66) | HTR2CHTR2BKDM1AHTR2ASLC6A2 | |
| SCHEMBL16569276 | 0.79 | HTR2C (0.41) | HTR2CHTR2BMAOBHTR2ASLC6A2 | |
| SCHEMBL19262111 | 0.79 | HTR2C (0.63) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL17080568 | 0.79 | HTR2C (0.41) | HTR2CHTR2BMAOBHTR2ASLC6A2 | |
| SCHEMBL22334928 | 0.79 | HTR2C (0.66) | HTR2CHTR2BKDM1AMAOBKCNH2 | |
| SCHEMBL13591154 | 0.79 | HTR2C (0.63) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-2822931-B1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2 INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9505728-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBVIE INC (US) | 2016-03-31 | — | — | US | disclosed |
| US-9186353-B2 | Treatment of osteoarthritis pain | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9108948-B2 | Cyclopropyl amine derivatives | ABBVIE INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150080412-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| CN-104398516-A | CYCLOPROPYL AMIDE DERIVATIVES TARGETING THE HISTAMINE H3 RECEPTOR | ASTRAZENECA AB | 2015-03-11 | — | — | CN | disclosed |
| EP-2049472-B1 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBVIE BAHAMAS LTD (BS) | 2015-01-21 | — | — | EP | disclosed |
| EP-2231631-A1 | CYCLOPROPYL AMINE DERIVATIVES | Abbott Laboratories (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009079225-A1 | CYCLOPROPYL AMINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | WO | disclosed |
| EP-2049472-A2 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | Abbott Laboratories (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080242653-A1 | Cyclopropyl amine derivatives | ABBVIE INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | ABBVIE INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007150010-A2 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-1737824-A2 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
| WO-2005103032-A2 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| EP-0369762-B1 | Pesticides | ROUSSEL UCLAF (FR) | 1993-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | HRH4, HRH3, HNMT | HTR2C 13/4885HTR2B 22/4885KDM1A 669/4885 |
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | HTR2C 1784/4885HTR2B 997/4885KDM1A 2361/4885 |
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | HRH3, HRH4, HRH2 | HTR2C 243/4885HTR2B 255/4885KDM1A 514/4885 |
| US-20150080412-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | HTR2C 2039/4885HTR2B 2372/4885KDM1A 2573/4885 |
| US-20080242653-A1 | Cyclopropyl amine derivatives | HRH3, HRH4, HRH2 | HTR2C 213/4885HTR2B 121/4885KDM1A 1513/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | HTR2C 1691/4885HTR2B 1058/4885KDM1A 2609/4885 |
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | HTR2C 301/4885HTR2B 250/4885KDM1A 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.